Thus, chitinase-1 inhibitor targeting chitinase-1 has been studied as a therapeutic options for airway inflammation and fibrosis in recent experimental airway-diseases models [13, 14]. This evidence concerns the gene CHIT1 and glycogen storage disease VI.